Structure via PubChem · Public domain (PubChem)
osilodrostat
Sign in to saveAlso known as LCI699, LCI-699
Osilodrostat, sold under the brand name Isturisa, is a medication used for the treatment of adults with Cushing's disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease. Osilodrostat is an orally active (taken by mouth), nonsteroidal corticosteroid biosynthesis inhibitor which was developed by Novartis for the treatment of Cushing's syndrome and pituitary hypersecretion (a specific subtype of Cushing's syndrome). It specifically acts as a potent and selective inhibitor of 11beta-hydroxylase (CYP11B1).
Chemical data
- Formula
- C13H10FN3
- Molecular weight
- 227.24 g/mol
- IUPAC name
- 4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile
- SMILES
- C1CC2=CN=CN2[C@H]1C3=C(C=C(C=C3)C#N)F
- InChIKey
- USUZGMWDZDXMDG-CYBMUJFWSA-N
- XLogP
- 1.9
- Polar surface area
- 41.6 Ų
- H-bond donors
- 0
- H-bond acceptors
- 3
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2020
- Admin. routes
- oral
- Indications
- liver disease, pituitary-dependent Cushing's disease, hypertension, Cushing syndrome
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 227.085876
Show 4 more facts
- chemical formula
- C₁₃H₁₀FN₃
- canonical SMILES
- C1CC2=CN=CN2C1C3=C(C=C(C=C3)C#N)F
- isomeric SMILES
- C1CC2=CN=CN2[C@H]1C3=C(C=C(C=C3)C#N)F
- physically interacts with
- cytochrome P450 family 11 subfamily B member 1
via Wikidata · CC0
~5 min read
Encyclopedic overview
8 sectionsContents
- History
- Society and culture
- Legal status
- Economics
- Research
- References
- Further reading
- External links
Osilodrostat, sold under the brand name Isturisa, is a medication used for the treatment of adults with Cushing's disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease. Osilodrostat is an orally active (taken by mouth), nonsteroidal corticosteroid biosynthesis inhibitor which was developed by Novartis for the treatment of Cushing's syndrome and pituitary hypersecretion (a specific subtype of Cushing's syndrome). It specifically acts as a potent and selective inhibitor of 11beta-hydroxylase (CYP11B1).
The most common side effects are adrenal insufficiency, headache, vomiting, nausea, fatigue, and edema (swelling caused by fluid retention).
Excerpted from Wikipedia’s “osilodrostat” article, available under the CC BY-SA 4.0 licence.